10/18/2024

Janusmed sex and gender

Janusmed sex and gender – aripiprazole monohydrate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Aripiprazole

Aripiprazole

Class : C

Show all info

Print

Contact us

  1. Abilify (aripiprazole). Full prescribing information. Food and Drug Administration [www]. [updated 2016-08-01, cited 2020-06-03].

  2. Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.

  3. Abilify (aripiprazole). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-05-07, 2020-06-23]

  4. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry . 2007;68(6):843-853.

  5. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol. 2008;28(2):156-65.

  6. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603-14.

  7. Stephen Marder, MD and T Scott Stroup, MD, MPH. Pharmacotherapy for schizophrenia: Side effect management. UpToDate [www]. [updated 2019-10-16, cited 2020-06-30].

  8. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Garcia-Unzueta MT, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophr Res. 2017;189:134-141.

  9. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.

  10. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Abilify (aripiprazole). Full prescribing information. Food and Drug Administration [www]. [updated 2016-08-01, cited 2020-06-03].
  2. Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.
  3. Abilify (aripiprazole). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-05-07, 2020-06-23]
  4. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry . 2007;68(6):843-853.
  5. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol. 2008;28(2):156-65.
  6. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603-14.
  7. Stephen Marder, MD and T Scott Stroup, MD, MPH. Pharmacotherapy for schizophrenia: Side effect management. UpToDate [www]. [updated 2019-10-16, cited 2020-06-30].
  8. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Garcia-Unzueta MT, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophr Res. 2017;189:134-141.
  9. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.
  10. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]